AHEAD OF THE CURVE ®

Trials and Triumphs of Gene Editing: A Compendium

Overview

While offering curative potential, much remains to be known about the long-term clinical activity and safety of gene editing therapies. We expect answers to these complex questions will continue to be a key investor focus as programs advance.

While the clinical and regulatory progress of gene therapies may inform the road ahead for gene editing, permanent genomic changes will likely yield distinct advantages and challenges. Advancements in editing efficiency, the characterization of on – and off -targeted editing, and pre -conditioning regimens are likely focus areas in the years ahead. We have identified nearly 190 gene editing programs across broad therapeutic areas.

You can download the Report here.

Contact

Headshot DB

Dierk
Beyer

Partner
M&A, Cowen

+49 69 5060 675 62
Email

Tobias
Levedag

Partner
M&A, Cowen

+49 89 2000 393 70
Email

Lars
Veit

Partner
M&A, Cowen

+49 89 2000 393 0
Email

Konstantin
Schönborn

Partner
M&A, Cowen

+49 89 2000 393 0
Email

Similar Insights

Pharma Services Report April
Insights Cowen Valued-Based Care Health Care Business Model Transformation